SYK

Stryker is one of the highest-quality franchises in large-cap medtech, anchored by scale advantages in Orthopaedics and MedSurg/Neurotechnology, deep hospital relationships, and a steady cadence of innovation and procedural pull-through. Its installed-base model in capital equipment (notably robotics) tends to create durable switching costs because hospitals standardize workflows, instrumentation, service, and surgeon training over multi-year cycles. Strategically, the definitive agreement to acquire care.ai (ambient intelligence and virtual care workflows) is a logical adjacency that can deepen Stryker’s “connected hospital” value proposition and improve differentiation beyond hardware, but it also increases software integration and execution complexity versus Stryker’s traditional device strengths. Industry-wise, the demand backdrop remains favorable: elective procedure volumes are resilient, hospitals continue to prioritize throughput and labor efficiency, and vendors that bundle capital equipment with recurring disposables and service are gaining share.

Financially, the most current company-reported snapshot available indicates Stryker exited 2025 with strong momentum: Q4 2025 net sales were about $7.17B (+11.4% y/y) and full-year 2025 net sales were about $25.12B (+11.2% y/y), with full-year organic growth of about +10.3%. Full-year 2025 adjusted EPS was $13.63 (+11.8% y/y) and Q4 2025 adjusted EPS was $4.47 (+11.5% y/y). Management guided to 2026 organic net sales growth of 8.0%–9.5% and adjusted EPS of $14.90–$15.10, but flagged a meaningful tariff headwind (about $400M for the year). On valuation, SYK at roughly $327 implies a high multiple (about 48x trailing EPS per current market data), so the stock is priced for continued high-single-digit organic growth plus consistent margin expansion; any wobble in procedure growth, capital budgets, or tariff mitigation could compress the multiple even if fundamentals remain solid. Dividend support is real but modest for this valuation profile: the annualized dividend is about $3.52 per share (roughly ~1% yield), with the next ex-dividend date shown as March 31, 2026.

Over the next 12 months, the core bull case is straightforward: if Stryker delivers on its 2026 guide (8%–9.5% organic growth and $14.90–$15.10 adjusted EPS) while sustaining margin expansion, the stock can work despite an elevated multiple because earnings growth remains visible and high-quality. The most important catalysts are continued strength in elective procedures and capital demand (robotics placements and related pull-through), evidence that tariff impacts can be mitigated through sourcing/price/mix, and early commercial traction or cross-selling benefits from care.ai as hospitals prioritize “smart room” and workflow automation. The key risks are also clear: tariff costs landing harder than expected (forcing price actions that could slow volume), a hospital capex pause that delays high-ticket system purchases, and the ever-present medtech risk set (regulatory actions, product quality issues, cybersecurity disruption, and M&A integration execution) that can quickly erode premium valuations.

Recommendation: HOLD. The business is high quality with credible 2026 growth and earnings guidance, but the current valuation leaves less room for error given the stated tariff headwind and the possibility of multiple compression if growth normalizes or hospital capital spending slows. I would look to upgrade on either a meaningful pullback that improves the risk/reward or clearer evidence over the next few quarters that Stryker can offset tariffs while maintaining the guided growth and margin trajectory.